猪肥胖基因cDNA的克隆与分析

肥胖基因（ａｂ）是近年刚被克隆的新基因,该基因产物Ｌｅｐｔｉｎ是反映体内脂肪含量和调节体重的重信号因子,首次报道猪ｏｂ基因全长序列,并对不同种物ｏｂ基因的同源性进行了比较,以λＵｎｉ－ＺＡＰ＾ＴＭ为载体构建了猪脂肪ｃＤＮＡ文库,根据已知的人和鼠ｏｂ基因序列设计ＰＣＲ引物,利用ＰＣＲ法筛选猪脂肪ｃＤＮＡ文库,并用ＲＴ－ＰＣＲ从脂肪ＲＮＡ中扩增的３６６ｂｐ猪ｏｂ基因片段作探针,获得了全长３２７７ｂｐ的     

日本血吸虫(中国大陆株)谷胱甘肽转移酶编码区基因的体外扩增、克隆及在原核细胞的高效表达

为表达、获取日本血吸早谷胱甘肽转移酶（ＳｊＧＳＴ）基因工程重组蛋白,以日本血吸虫（中国大陆株）ｃＤＮＡ为模板,设计、合成特定寡核苷酸引物,ＲＴ－ＰＣＲ法扩增ＧＳＴ编码基因序列,将扩增产物连接ｐＧＥＭ－Ｔ克隆载体,再亚克隆到真、原核表达质粒ｐＢＫ－ＣＭＶ中,转染大肠杆菌ＸＬ１－ｂｌｕｅ,经ＩＰＴＧ诱导后用ＳＤＳ－ＰＡＧＥ分析表达效果。结果 ＲＴ－ＰＣＲ法特异性扩增出日本血吸虫ＧＳＴ编码区基因片段,其     

人碱性成纤维细胞生长因子基因克隆,cDNA5‘端修饰及在大 …

采用ｃＤＮＡ－ＰＣＲ技术,从人胎盘ｃＤＮＡ文库ＤＮＡ中克隆了人碱性成纤维在子（ｈｂＦＧＦ）基因,用ＰＣＲ突变法对其５＆端序列进行修饰,奖天然和修饰后的ｈｂＦＧＦ基因分别克隆至表达载体ｐＢＶ２２１,免疫抑迹和ＳＤＳ－ＰＡＧＥ结果证明,经修饰后的基因在大肠杆菌ＤＳ５α中获得了表达,表达量占菌体总蛋白９％。     

汉滩病毒S基因及其5‘端真核表达载体的构建及在细胞中的表达

体外研究汉滩病毒（ＨＴＮＶ）Ｓ基因及其５'端表达的意义,为核蛋　白Ｔ细胞表位的研究奠定基础。设计２套引物,用ＰＣＲ方法从ＰＢＶ２２０－Ｓ２２原核质粒中扩增出Ｓ　基因全读码框（３７－１３２６ｂｐ）及Ｓ基因５'端（３７－５０１ｂｐ）,用ＴＡ克隆将其克隆入ｐｃＤＮＡ３．１／Ｖ５－Ｈｉｓ－ＴＯＰＯ载体中,成功构建ｐｃＤＮＡ３．１－Ｓ及ｐｃＤＮＡ３．１－Ｓ－Ｎ真核表达载体,并通过脂质体转　染至Ｖｅｒｏ细胞中,进行了瞬时表达。间接免疫荧光成功检测到ｐｃＤＮＡ３．１－Ｓ及ｐｃＤＮＡ３．１－Ｓ－Ｎ在Ｖｅｒｏ细胞中的表达。ｐｃＤＮＡ３．１－Ｓ及ｐｃＤＮＡ３．１－Ｓ－Ｎ真核表达载体有较高的转染效率,目　的基因能在宿主细胞中表达,有利于研究ＨＴＮＶ－Ｓ基因在Ｔ细胞表位研究中的意义。     

鲤鱼生长激素基因的改造及其在大肠杆菌中的表达

用聚合酶链式反应（ＰＣＲ）改造了锂鱼生长激素基因,扩增出编码锂鱼生长激素成熟肽的序列,并将此序列克隆到ｐＢｌｕｅｓｃｒｉｐｔ Ⅱ ＫＳ质粒中,序列分析后,亚克隆到大肠杆菌表达载体ｐＢＶ２２０中。经ＳＤＳ－ＰＡＧＥ和薄层扫描,结果表明锂鱼生长激素基因已大肠杆菌中获得表达。锂鱼生长激素成熟肽的分子量为２２０００道尔顿,表达率占细胞总蛋白的１８％以上％。     

人白细胞介素—18基因的克隆及其在大肠杆菌中的表达

利用反转录ＰＣＲ（ＲＴＰＣＲ）法从人肝组织中分离人白介素１８（ｈＩＬ１８）基因。克隆到Ｔｖｅｃｔｏｒｅａｓｙ载体中,经酶切初步鉴定后进行ＤＮＡ序列分析,结果表明与文献报道完全一致。以ｐＢＶ２２０为表达载体,在大肠杆菌中高效表达了ｈＩＬ１８基因,重组蛋白占菌体总蛋白的２７．２％。为进一步研究其生物活性奠定了重要基础。     

野生型和突变型p16在H460细胞株的表达

应用ＰＣＲ体外定点突为技术,构建了ｐ１６－Ｐ４８Ｌ和ｐ１６－Ｄ７４ｎ突变体。野生型和突变型ｐ１６ｃＤＮＡ克隆地ｐｃＤＮＡ３真核表达载体,导入纯合缺失ｐ１６基因的人肺癌细胞株Ｈ４６０,经ＲＮＡ点杂交初筛吴Ｇ４１８抗性的细胞株,再用Ｎｏｒｔｈｅｒｎ印迹证实外源ｐ１６表达。     

人生长激素基因的cDNA克隆,原核高效表达及纯化

用ＲＴ－ＰＣＲ方法,从含有全长人生长激素（ＨＧＨ）基因的ＣＨＯ细胞中获得ｈｇｈ的ｃＤＮＡ,将其克隆入ｐＥＴ－１１ｂ载体中,在大肠杆菌中获得高效表达,表达量占菌体蛋白总量的２０％。经色谱纯化后,纯度大于９５％。     

猪圆环病毒2型ORF2基因序列分析及真核表达载体的构建

根据ＧｅｎＢａｎｋ中猪圆环病毒２型（ＰＣＶ－２）ＯＲＦ２基因序列,设计一　对引物,应用ＰＣＲ从疑患断奶仔猪多系统消耗综合症（ＰＭＷＳ）的死亡仔猪组织病料中扩增出ＯＲＦ　２全基因（７０２ｂｐ）。将此片段克隆入ｐＧＥＭ－Ｔ　ｅａｓｙ载体,筛选获得重组质粒ｐＴＯＲＦ２,并对此质　粒中的插入序列进行了测序分析,结果表明本试验克隆的ＯＲＦ２与美国ＰＣＶ－２分离株ＡＦ２６４０３９　的核苷酸及氨基酸序列同源性均达到１００％,与其他ＰＣＶ－２毒株同源性分别为９２．３％～９８．　６％和　９２．３％～９６．６％。重组质粒ｐＴＯＲＦ２经　Ｂａｍ　Ｈ　Ｉ、Ｅｃｏ　Ｒ　Ｖ双酶切,回收ＯＲＦ２基因,转　移入真　核表达载体ｐＳｅｃＴａｇ２／ＨｙｇｒｏＢ的相应酶切位点之间,构建成重组质粒ｐＳｅｃＴａｇＯＲＦ２。此重组表　达载体的构建成功为进一步研究ＯＲＦ２编码蛋白的生物学活性及建立ＰＣＶ诊断试剂盒打下基础。     

胶质细胞衍生的神经营养因子成熟肽基因的克隆、表达及纯化的研究

通过ＰＣＲ的方法克隆了胶质细胞衍生的神经营养因子（ｇｌｉａｃｅｌ－ｌｉｎｅｄｅｒｉｖｅｄｎｅｕ－ｒｏｔｒｏｐｈｉｃｆａｃｔｏｒ,ＧＤＮＦ）成熟肽的基因,并将其连接到Ｅ．ｃｏｌｉ高效表达载体ｐＥＴ１６ｂ,在Ｅ．ｃｏｌｉ中获得高效表达．表达蛋白占菌体总蛋白２１％以上,以包涵体形式存在,经体外复性后用金属螯合亲和层析的方法得到具有较高纯度和活性ｒｈＧＤＮＦ．     

人ob基因克隆及其亚细胞定位的研究

目的:旨在克隆人肥胖(obese,ob)基因的全长cDNA序列,与EGFP重组构建融合蛋白表达载体,并分析其亚细胞水平的定位.方法:提取人脂肪细胞总RNA,采用RT-PCR方法扩增出人ob基因cDNA,并克隆至真核表达载体pEGFP-CI,重组质粒转染NIH-3T3细胞,荧光显微镜分析EGFP-ob融合蛋白的亚细胞定位.结果:克隆的ob基因cDNA为501bp,共编码167个氨基酸,与GenBank公布的人ob基因序列一致,荧光显微镜分析表明,重组的EGFP-ob融合蛋白主要分布于NIT-3T3的细胞质中.结论:成功克隆了人OB基因的cDNA序列,构建人OB基因的真核表达载体pEGFP-CI-ob,融合蛋白EGFP-ob定位于NIH-3T3细胞质中.     

Potentiation of response to insulin and anti-insulin action by two human pituitary peptides in lean agouti A/a, obese yellow Avy/A, and C57BL/6J-ob/ob mice

Insulin-like and anti-insulin effects of human growth hormone (hGH) were examined by determining the effects of two peptides representing portions of the hGH molecule in lean agouti A/a and obese yellow Avy/A and ob/ob mice. The peptides were the amino terminal segment, residue 1-43 (hGH1-43), which has been shown to potentiate the response to insulin and another peptide, hyperglycemic peptide (HP), with unknown structure, which has anti-insulin activity. The anti-insulin component is an acidic low molecular weight peptide which co-purifies with hGH but was not recognized by antibodies to intact hGH and did not cross-react with anti-hGH1-43 antiserum. The purpose of these studies was to further understand the multiple actions of hGH and its acute and chronic effects on response to insulin. Injections of hGH1-43 dramatically enhanced the effect of insulin on glucose clearance of obese yellow Avy/A and ob/ob mice and increased the insulin-stimulated glucose oxidation in adipose tissue of yellow mice, but had no direct effect on blood glucose or insulin levels of either genotype. Administration of HP to obese yellow mice produced hyperglycemia and suppressed serum insulin concentrations. Tissues from lean agouti and obese yellow mice treated with HP in vitro showed decreased basal and insulin-stimulated glucose oxidation as well as decreased 14C incorporation into lipids. Chronic treatment of obese yellow and ob/ob mice with HP increased fasting blood glucose and impaired glucose tolerance. The effect of HP was more pronounced in obese yellow mice and the ob/ob mice were more sensitive to the diabetogenic actions of intact hGH. These data provide further evidence for the existence of two opposing biologic activities derived from disparate amino acid sequences in hGH. Additionally, the data indicate that assays using obese yellow Avy/A mice can distinguish the effects of hGH from those of the individual peptides to a greater degree than assays using obese ob/ob mice.     

Role of CC chemokine receptor 2 in bone marrow cells in the recruitment of macrophages into obese adipose tissue

The MCP-1 (monocyte chemoattractant protein-1)/CCR2 (CC motif chemokine receptor-2) pathway may play a role in macrophage infiltration into obese adipose tissue. Here we investigated the role of CCR2 in the recruitment of bone marrow-derived macrophages into obese adipose tissue in vitro and in vivo. Using the TAXIScan device, which can measure quantitatively the directionality and velocity of cell migration at time lapse intervals in vitro, we demonstrated that bone marrow cells (BMCs) from wild type mice migrate directly toward MCP-1 or culture medium conditioned by adipose tissue explants of genetically obese ob/ob mice, which are efficiently suppressed by pharmacological blockade of CCR2 signaling. The number of F4/80-positive macrophages was reduced in the adipose tissue from high fat diet-fed obese KKAy or ob/ob mice treated with a CCR2 antagonist propagermanium relative to vehicle-treated groups. We also found that the number of macrophages is reduced in the adipose tissue from ob/ob mice reconstituted with CCR2(-/-) BMCs (ob/ob + CCR2(-/-) BMCs) relative to those with CCR2+/+ BMCs (ob/ob + CCR2+/+ BMCs). Expression of mRNAs for CD11c and TLR4 (Toll-like receptor 4) markers of proinflammatory M1 macrophages was also decreased in the adipose tissue from ob/ob + CCR2(-/-) BMCs relative to ob/ob + CCR2+/+ BMCs, whereas mannose receptor and CD163, markers of anti-inflammatory M2 macrophages, were unchanged. This study provides in vivo and in vitro evidence that CCR2 in bone marrow cells plays an important role in the recruitment of macrophages into obese adipose tissue.     

Influence of genetic obesity in mice on the lipolytic response of isolated adipocytes to isoproterenol and ACTH-(1-24).

The lipolytic response of isolated adipocytes from genetic obese (C57/BL/64 ob/ob) and lean (C57BL/6J +/?) mice to ACTH-(1-24), isoproterenol and glucagon has been studied. The mean cell idameter of adipocytes form ob/ob mice was approximately twice that of lean controls. The adipocytes from obese mice contained on the average approximately six times the amount of triacylglycerol present in the smaller lean mouse adipocyte. Lipolysis was calculated both on a per cell basis (10(5) cells) and per mu mole of triacylglycerol and when expressed on a cell number basis, the larger adipocytes from obese mice showed an ACTH-(1-24) stimulated glycerol release which was quantitatively similar to that of smaller adipocytes from lean mice. When expressed per mu mole of triacylglycerol, the smaller cells from lean animals appeared to be dramatically more responsive to either isoproterenol or ACTH-(1-24). On either basis, ACTH-(1-24) stimulated glycerol release from obese mouse cells was greater than the isoproterenol response. The obese mouse of adipocyte showed selective loss of response to isoproterenol compared to its lean control.     

Leptin attenuates gene expression for renal 25-hydroxyvitamin D3-1alpha-hydroxylase in mice via the long form of the leptin receptor

Leptin, the ob gene product secreted by adipocytes, controls overall energy balance. We previously showed that leptin administration to leptin-deficient obese (ob/ob) mice suppressed mRNA expression and activity of renal 25-hydroxyvitamin D(3)-1alpha-hydroxylase (CYP27B1). In leptin receptor-deficient (db/db) mice, we presently examined whether leptin affects 1alpha-hydroxylase expression in renal tubules through the active form of the leptin receptor (ObRb). Elevated serum concentrations of calcium and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] in untreated ob/ob mice showed sharp reduction with leptin administration (4 mg/kg, i.p. every 12h for 2 days); no such reduction of elevation occurred in db/db mice. ObRb mRNA was expressed in kidney, brain, fat, lung, and bone in wild-type and ob/ob mice, but not db/db mice. The ob/ob and db/db mice showed large increases in renal 1alpha-hydroxylase mRNA expression and activity. Leptin administration (4 mg/kg) completely abrogated these increases in ob/ob but not db/db mice. Renal 25-hydroxyvitamin D(3)-24-hydroxylase (CYP24) mRNA synthesis also was greatly elevated in ob/ob and db/db mice; excesses decreased significantly with leptin administration in ob/ob mice, but increased in db/db mice. Renal tubular cells in primary culture expressed mRNAs including proximal tubules markers (1alpha-hydroxylase and megalin), parathyroid hormone receptor, and vitamin D receptor. Calcitonin receptor mRNA, synthesized mainly in distal tubules, was scant, indicating that most cultured cells were from proximal tubules. Cells did not express ObRb mRNA. Forskolin exposure at 10(-6)M for 3 or 6h significantly increased 1alpha-hydroxylase mRNA. Leptin at 10(-6)M did not change mRNA expression in either presence or absence of forskolin. Accordingly, leptin attenuates renal 1alpha-hydroxylase gene expression through ObRb. Furthermore, leptin appears to act indirectly on renal proximal tubules to regulate 1alpha-hydroxylase gene expression.     

Leptin treatment markedly increased plasma adiponectin but barely decreased plasma resistin of ob/ob mice

Adiponectin (ApN) and leptin are two adipocytokines that control fuel homeostasis, body weight, and insulin sensitivity. Their interplay is still poorly studied. These hormones are either undetectable or decreased in obese, diabetic ob/ob mice. We examined the effects of leptin treatment on ApN gene expression, protein production, secretion, and circulating levels of ob/ob mice. We also briefly tackled the influence of this treatment on resistin, another adipocytokine involved in obesity-related insulin resistance. Leptin-treated (T) obese mice (continuous sc infusion for 6 days) were compared with untreated lean (L), untreated obese (O), and untreated pair-fed obese (PF) mice. Blood was collected throughout the study. At day 3 or day 6, fat pads were either directly analyzed (mRNA, ApN content) or cultured for up to 24 h (ApN secretion). The direct effect of leptin was also studied in 3T3-F442A adipocytes. Compared with L mice, ApN content of visceral or subcutaneous fat and ApN secretion by adipose explants were blunted in obese mice. Accordingly, plasma ApN levels of O mice were decreased by 50%. Leptin treatment of ob/ob mice increased ApN mRNAs, ApN content, and secretion from the visceral depot by 50-80%. Leptin also directly stimulated ApN mRNAs and secretion from 3T3-F442A adipocytes. After 6 days of treatment, plasma ApN of ob/ob mice increased 2.5-fold, a rise that did not occur in PF mice. Plasma resistin of T mice was barely decreased. Leptin treatment, but not mere calorie restriction, corrects plasma ApN in obese mice by restoring adipose tissue ApN concentrations and secretion, at least in part, via a direct stimulation of ApN gene expression. Such a treatment only minimally affects circulating resistin. ApN restoration could, in concert with leptin, contribute to the metabolic effects classically observed during leptin administration.     

Persistence of high density lipoprotein particles in obese mice lacking apolipoprotein A-I

Obese mice without leptin (ob/ob) or the leptin receptor (db/db) have increased plasma HDL levels and accumulate a unique lipoprotein referred to as LDL/HDL1. To determine the role of apolipoprotein A-I (apoA-I) in the formation and accumulation of LDL/HDL1, both ob/ob and db/db mice were crossed onto an apoA-I-deficient (apoA-I(-/-)) background. Even though the obese apoA-I(-/-) mice had an expected dramatic decrease in HDL levels, the LDL/HDL1 particle persisted. The cholesterol in this lipoprotein range was associated with both alpha- and beta-migrating particles, confirming the presence of small LDLs and large HDLs. Moreover, in the obese apoA-I(-/-) mice, LDL particles were smaller and HDLs were more negatively charged and enriched in apoE compared with controls. This LDL/HDL1 particle was rapidly remodeled to the size of normal HDL after injection into C57BL/6 mice, but it was not catabolized in obese apoA-I(-/-) mice even though plasma hepatic lipase (HL) activity was increased significantly. The finding of decreased hepatic scavenger receptor class B type I (SR-BI) protein levels may explain the persistence of LDL/HDL1 in obese apoA-I(-/-) mice. Our studies suggest that the maturation and removal of large HDLs depends on the integrity of a functional axis of apoA-I, HL, and SR-BI. Moreover, the presence of large HDLs without apoA-I provides evidence for an apoA-I-independent pathway of cholesterol efflux, possibly sustained by apoE.     

Obesity causes very low density lipoprotein clearance defects in low-density lipoprotein receptor-deficient mice

We have reported that obese leptin-deficient mice (ob/ob) lacking the low-density lipoprotein receptor (LDLR(-/-)) develop severe hyperlipidemia and spontaneous atherosclerosis. In the present study, we show that obese leptin receptor-deficient mice (db/db) lacking LDLR have a similar phenotype, even in the presence of elevated plasma leptin levels. We investigated the mechanism for the hyperlipidemia in obese LDLR(-/-) mice by comparing lipoprotein production and clearance rates in C57BL/6, ob/ob, LDLR(-/-) and ob/ob;LDLR(-/-) mice. Hepatic triglyceride production rates were equally increased ( approximately 1.4-fold, P<.05) in both LDLR(-/-) and ob/ob;LDLR(-/-) mice compared to C57BL/6 and ob/ob mice. LDL clearance was decreased ( approximately 1.3- fold, P<.01) to a similar extent in LDLR(-/-) and ob/ob;LDLR(-/-) mice compared to C57BL/6 and ob/ob controls. While VLDL clearance was delayed in LDLR(-/-) compared to C57BL/6 and ob/ob mice (2-fold, P<.001), this delay was exaggerated in ob/ob;LDLR(-/-) mice (3.8-fold, P<001). The VLDL clearance defects were due to decreased hepatic uptake compared to C57BL/6 (54% and 26% for LDLR(-/-) and ob/ob;LDLR(-/-), respectively, P<.001). When VLDL was collected from C57BL/6, ob/ob, LDLR(-/-), and ob/ob;LDLR(-/-) donors and injected into LDLR(-/-) recipient mice, counts remaining in the liver were 1.4-fold elevated in mice receiving LDLR(-/-) VLDL and 2-fold increased in mice receiving ob/ob;LDLR(-/-) VLDL compared to controls receiving C57BL/6 VLDL (P<.01). Thus, the increase in plasma lipoproteins in ob/ob;LDLR(-/-) mice is caused by delayed VLDL clearance. This appears to be due to defects in both the liver and the lipoproteins themselves in these obese mice.     

Stearoyl-CoA desaturase-1 deficiency attenuates obesity and insulin resistance in leptin-resistant obese mice

Obesity and adiposity greatly increase the risk for secondary conditions such as insulin resistance. Mice deficient in the enzyme stearoyl-CoA desaturase-1 (SCD1) are lean and protected from diet-induced obesity and insulin resistance. In order to determine the effect of SCD1 deficiency on various mouse models of obesity, we introduced a global deletion of the Scd1 gene into leptin-deficient ob/ob mice, leptin-resistant Agouti (A^y/a) mice, and high-fat diet-fed obese (DIO) mice. SCD1 deficiency lowered body weight, adiposity, hepatic lipid accumulation, and hepatic lipogenic gene expression in all three mouse models. However, glucose tolerance, insulin, and leptin sensitivity were improved by SCD1 deficiency only in A^y/a and DIO mice, but not ob/ob mice. These data uncouple the effects of SCD1 deficiency on weight loss from those on insulin sensitivity and suggest a beneficial effect of SCD1 inhibition on insulin sensitivity in obese mice that express a functional leptin gene.     

Abnormally decreased NO and augmented CO production in islets of the leptin-deficient ob/ob mouse might contribute to explain hyperinsulinemia and islet survival in leptin-resistant type 2 obese diabetes

The role of the gaseous messengers NO and CO for β-cell function and survival is controversial. We examined this issue in the hyperglycemic-hyperinsulinemic ob/ob mouse, an animal model of type 2 obese diabetes, by studying islets from obese vs lean mice regarding glucose-stimulated insulin release in relation to islet NO and CO production and the influence of modulating peptide hormones. Glucose-stimulated increase in ncNOS-activity in incubated lean islets was converted to a decrease in ob/ob islets associated with markedly increased insulin release. Both types of islets displayed iNOS activity appearing after ~60 min in high-glucose. In ob/ob islets the insulinotropic peptides glucagon, GLP-1 and GIP suppressed NOS activities and amplified glucose-stimulated insulin release. The insulinostatic peptide leptin induced the opposite effects. Suppression of islet CO production inhibited, while stimulation amplified glucose-stimulated insulin release. Nonincubated isolated islets from young and adult obese mice displayed very low ncNOS and negligible iNOS activity. In contrast, production of CO, a NOS inhibitor, was impressively raised. Glucose injections induced strong activities of islet NOS isoforms in lean but not in obese mice and confocal microscopy revealed iNOS expression only in lean islets. Islets from ob/ob mice existing in a hyperglycemic in vivo milieu maintain elevated insulin secretion and protection from glucotoxicity through a general suppression of islet NOS activities achieved by leptin deficiency, high CO production and insulinotropic cyclic-AMP-generating hormones. Such a beneficial effect on islet function and survival might have its clinical counterpart in human leptin-resistant type 2 obese diabetes with hyperinsulinemia.